Meeting
2019 ASCO Annual Meeting
Efficacy and a novel clinicopathologic-genomic nomogram of atezolizumab in advanced non-small cell lung cancer (POPLAR and OAK): A combined analysis of two multicenter, randomized, phase II/III trials.
Authors
Yunfang Yu
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
Yunfang Yu , Yongjian Chen , Anlin Li , Qiyun Ou , Ying Wang , Wei Ren , Wenda Zhang , Yujie Tan , Herui Yao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2573)
DOI
10.1200/JCO.2019.37.15_suppl.2573
Abstract #
2573
Poster Bd #
217
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.
First Author: Antoine Italiano
Poster
2022 ASCO Annual Meeting
Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial.
First Author: Alessio Cortellini
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse
First Author: Salah-Eddin Al-Batran